Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1

References

• HIV/AIDS fact sheet. World Health Organization. [ Updated 2017 July; cited 2017 Nov 22]. Available from: http://www.who.int/mediacentre/factsheets/fs360/en/
   Google Scholar
• Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998;177(1):40.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366(9483):378.
   PubMed Web of Science ®Google Scholar
• Beyrer C, Baral SD, van Griensven F, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet. 2012 Jul 28;380(9839):367–377.
   PubMed Web of Science ®Google Scholar
• Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015 Feb 5;372(6):509–518.
   PubMed Web of Science ®Google Scholar
• Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012 Aug 2;367(5):411–422.
   PubMed Web of Science ®Google Scholar
• Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30;363(27):2587–2599.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012 Aug 2;367(5):399–410.
   PubMed Web of Science ®Google Scholar
• Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015 Dec;373(23):2237–2246.
   PubMed Web of Science ®Google Scholar
• McCallister S, Magnuson D, Guzman R, et al. HIV-1 seroconversion across 17 international demonstration projects using pre-exposure prophylaxis (PrEP) with oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF). Session 371; 2016 June 16–20; Boston, MA: Published at ASM Microbe.
   Google Scholar
• Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. United States Department of Health and Human Services. Washington, D.C. [ Updated 2017 Oct 17; cited 2017 Nov 22]. Available from https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0
   Google Scholar
• Guidelines for the treatment of adult HIV positive persons. European AIDS Clinical Society. Brussels, Belgium. [ Updated 2017 Oct; cited 2018 Feb 19]. Available from http://www.eacsociety.org/files/guidelines_9.0-english.pdf
   Google Scholar
• Shah BM, Schafer JJ, Desimone JA Jr. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy. 2014 May;34(5):506–520.
   PubMed Web of Science ®Google Scholar
• Pre-exposure prophylaxis (PrEP). Centers for Disease Control and Prevention. Atlanta, GA. [ Last updated 2017 Aug 31; cited 2017 Nov 22]. Available from https://www.cdc.gov/hiv/risk/prep/index.html
   Google Scholar
• De Clercq E. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. Int J Biochem Cell Biol. 2004;36:1800–1822.
   PubMed Web of Science ®Google Scholar
• Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nature Reviews Drug Discovery. 2005;4:236–248.
   PubMed Web of Science ®Google Scholar
• Marchand C, Maddali K, Métifiot M, et al. HIV-1 IN inhibitors: 2010 update and perspectives. Curr Top Med Chem. 2009;9(11):j1016–37.
   PubMed Web of Science ®Google Scholar
• Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials. 2013;14(5):192–203.
   PubMed Web of Science ®Google Scholar
• Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-daymonotherapy in HIV-1-infected adults. Aids. 2011 Sep 10;25(14):1737–1745.
   PubMed Web of Science ®Google Scholar
• Underwood MR, Johns BA, Sato A, et al. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):297–301.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24 week results of the VIKING study. J Infect Dis. 2013 Mar 1;207(5):740–748.
   PubMed Web of Science ®Google Scholar
• Trezza L, Ford SL, Spreen W, et al. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS. 2015;10(4):239–245.
   PubMed Web of Science ®Google Scholar
• Reese MJ, Bowers GD, Humphreys JE, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2016;46(5):445–456.
   PubMed Web of Science ®Google Scholar
• Müller RH, Gohla S, Keck CM. State of the art of nanocrystals – special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm. 2011 May;78(1):1–9.
   PubMed Web of Science ®Google Scholar
• Andrews CD, Spreen WR, Mohri H, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014 Mar 7;343(6175):1151–1154.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Brinson CC, Smith GHR, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015 Oct;15(10):1145–1155.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96 week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet Infect Dis Lancet. 2017 Sep 23;390(10101):1499–1510.
   PubMed Web of Science ®Google Scholar
• Landovitz R, Li S, Grinsztejn B, et al. Safety, tolerability and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected women and men: HPTN 077. Abstract 5481; 2017 July 23–26; Paris, France: Published International AIDS Society Conference.
   Google Scholar
• Ford SL, Sutton K, Lou Y, et al. Effect of rifampin on the single-dose pharmacokinetics of oral cabotegravir in healthy subjects. Antimicrob Agents Chemother. 2017 Sep 22;61:10.
   Web of Science ®Google Scholar
• Parasrampuria R, Ford S, Lou Y, et al. Pharmacokinetics of cabotegravir in subjects with severe renal impairment. Abstract 1389; 2017 Oct 4–8; San Diego, CA: Published at IDWEEK.
   Google Scholar
• Sadik J, Shaik B, Ford SL, et al. Pharmacokinetics of cabotegravir in subjects with moderate hepatic impairment. Abstract 1388; 2017 Oct 4–8; San Diego, CA: Published at IDWEEK.
   Google Scholar
• Eron JJ, Margolis DA, Gonzalez-Garcia J, et al. Safety and efficacy of long-acting CAB and RPV as two drug IM maintenance therapy: LATTE-2 week 96 results. Abstract 5628; 2017 July 23–26; Paris, France: Published International AIDS Society Conference.
   Google Scholar
• Radzio J, Spreen W, Yueh YL, et al. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med. 2015 Jan 14;7(270):270ra5.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017 Aug;4(8):e331–e340.
   PubMed Web of Science ®Google Scholar
• Study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus long-acting rilpivirine from current antiretroviral regimen in virologically suppressed HIV-1-infected adults. National Institutes of Health. U.S. National Library of Medicine. [ Updated 2017 Oct 23; cited 2017 Nov 22]. Available from https://clinicaltrials.gov/ct2/show/NCT02951052
   Google Scholar
• Study to evaluate the efficacy, safety, and tolerability of long-acting intramuscular cabotegravir and rilpivirine for maintenance of virologic suppression following switch from an integrase inhibitor in HIV-1 infected therapy naive participants. National Institutes of Health. U.S. National Library of Medicine. [ Updated 2017 Nov 17; cited 2017 Nov 22]. Available from https://clinicaltrials.gov/ct2/show/NCT02938520
   Google Scholar
• Efficacy, safety and tolerability study of long-acting Cabotegravir plus long-acting rilpivirine (CAB LA + RPV LA) in human-immunodeficiency virus-1 (HIV-1) infected adults. National Institutes of Health. U.S. National Library of Medicine. [ Updated 2017 Nov 22; cited 2017 Nov 22]. Available from https://clinicaltrials.gov/ct2/show/NCT03299049?term=atlas+2m&rank=1
   Google Scholar
• Safety and efficacy study of injectable cabotegravir compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), for pre-exposure prophylaxis in HIV-uninfected cisgender men and transgender women who have sex with men. National Institutes of Health. U.S. National Library of Medicine. [ Updated 2017 Oct 3; cited 2017 Dec 8] Available at https://clinicaltrials.gov/ct2/show/NCT02720094
   Google Scholar
• Evaluating the safety and efficacy of long-acting injectable cabotegravir compared to daily oral TDF/FTC for pre-exposure prophylaxis in HIV-uninfected women. National Institutes of Health. U.S. National Library of Medicine. [ Updated 2017 Dec 1; cited 2017 Dec 8]. Available from https://clinicaltrials.gov/ct2/show/NCT03164564
   Google Scholar
• Lou Y, Gould E, Fu C, et al. Cabotegravir (CAB) safety meta-analysis update from 14 phase I/IIa studies. Abstract 58845; 2016 Oct 26–30; New Orleans, LA: Published at: IDWeek.
   Google Scholar